The invention relates to antagonists of the adenosine A receptor, which can be used for the preparation of medicaments for auricular fibrillation in mammals, including humans. It has been found that the A adenosine receptor is present in human auricular cardiomyocytes and involved in the basic pathological mechanisms of auricular fibrillation. The use of A antagonists is advantageous over other known agents in that A antagonists are directed specifically to patients with auricular fibrillation.
